- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04023409
The Identification of Phenotypes in Patients With Severe Chronic Obstructive Pulmonary Disease (Groningen Severe COPD Cohort)
Rationale: Chronic Obstructive Pulmonary Disease (COPD) is defined by airway obstruction. However, the degree of airflow limitation does not adequately describe the complexity of COPD because significant heterogeneity exists between patients with respect to their clinical presentation, physiology, imaging, response to therapy, decline in lung function and survival. Currently, a clear alternative for describing COPD does not exist but the identification of subgroups of COPD patients based on clinical or genomic and epigenomic factors (phenotypes) could be useful. The continuous flow of very severe COPD patients to the UMCG gives the investigators the unique opportunity to perform a study on the phenotypes of very severe COPD and the underlying gene-environment interaction. The investigators anticipate that the findings of this study will lead to an earlier identification of those subjects who are at risk to develop severe or very severe COPD. In addition, it will lead to a better clinical characterisation of established COPD, possibly enabling a more tailored treatment of different COPD subphenotypes.
Objectives:
Primary Objective:
To identify new clinical phenotypes in patients with severe chronic obstructive pulmonary disease (COPD) using a cluster analysis.
Secondary Objectives:
To:
- identify clinical phenotypes (based on e.g. lung function, clinical, radiologic, systemic, pathological and immunological parameters) in patients with severe COPD.
- identify endotypes/ intermediate phenotypes in patients with severe COPD.
- investigate the contribution of (epi)genomics (including genetics and gene expression) to characterize patients with subsets of severe COPD.
Study design: Observational cross-sectional study with a 2 phase design
Study population: Patients with severe COPD who are referred to the UMCG for a consultation on lung transplantation or bronchoscopic lung volume reduction.
Aperçu de l'étude
Description détaillée
Rationale: Chronic Obstructive Pulmonary Disease (COPD) is defined by airway obstruction. However, the degree of airflow limitation does not adequately describe the complexity of COPD because significant heterogeneity exists between patients with respect to their clinical presentation, physiology, imaging, response to therapy, decline in lung function and survival. Currently, a clear alternative for describing COPD does not exist but the identification of subgroups of COPD patients based on clinical or genomic and epigenomic factors (phenotypes) could be useful. The continuous flow of very severe COPD patients to the UMCG gives the investigators the unique opportunity to perform a study on the phenotypes of very severe COPD and the underlying gene-environment interaction. The investigators anticipate that the findings of this study will lead to an earlier identification of those subjects who are at risk to develop severe or very severe COPD. In addition, it will lead to a better clinical characterisation of established COPD, possibly enabling a more tailored treatment of different COPD subphenotypes.
Objectives:
Primary Objective:
To identify new clinical phenotypes in patients with severe chronic obstructive pulmonary disease (COPD) using a cluster analysis.
Secondary Objectives:
To:
- identify clinical phenotypes (based on e.g. lung function, clinical, radiologic, systemic, pathological and immunological parameters) in patients with severe COPD.
- identify endotypes/ intermediate phenotypes in patients with severe COPD.
- investigate the contribution of (epi)genomics (including genetics and gene expression) to characterize patients with subsets of severe COPD.
Study design: Observational cross-sectional study with a 2 phase design
Study population: Patients with severe COPD who are referred to the UMCG for a consultation on lung transplantation or bronchoscopic lung volume reduction.
Main study parameters: The main study parameter is the identification of new clinical phenotypes. The collected data will allow us to identify new phenotypes, clusters of patients with comparable characteristics. These phenotypes are potentially based on a combination of lung function, clinical, radiologic, systemic and genomic parameters and endotypes, in patients with severe COPD.
Type d'étude
Inscription (Réel)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Referral to the LVR intervention team or LTx team of the (UMCG).
- Chronic Obstructive Pulmonary Disease (COPD) according the Global initiative for Chronic Obstructive Lung Disease (GOLD) criteria (post bronchodilator FEV1/FVC < 0.7)[1]
- Written informed consent.
Exclusion Criteria:
- There are no exclusion criteria for this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cohorte
- Perspectives temporelles: Transversale
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
Severe COPD patients
Patients with severe COPD who are referred to the UMCG for a consultation on lung transplantation or bronchoscopic lung volume reduction.
|
NA: no intervention
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
clinical phenotypes
Délai: baseline
|
To identify new clinical phenotypes in patients with severe chronic obstructive pulmonary disease (COPD) using a cluster analysis.
|
baseline
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Dirk-Jan Slebos, MD PhD, UMCG
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NL46286.042.14
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur MPOC sévère
-
Acibadem UniversityComplétéDémarche | La maladie de Sever | Apophysite calcanéenneTurquie
-
University of Colorado, DenverComplété
-
Fundacion PodoactivaComplétéLa maladie de Sever | Apophysite calcanéenneEspagne
-
Fraunhofer-Institute of Toxicology and Experimental...Institute for Pharmacology and Toxicology, RWTH AachenComplétéVolontaires en bonne santé | COPD GOLD I à IV | Asthme GINA 1 à 4Allemagne
-
Ann & Robert H Lurie Children's Hospital of ChicagoAmerican Medical Society for Sports MedicineInconnueSyndrome d'Osgood-Schlatter | Syndrome de Sinding-Larsen et Johansson | La maladie de Sever | ApophysiteÉtats-Unis
-
University of DelawareRecrutementLa maladie de Sever | Tendinopathie d'Achille | Tendinopathie d'insertion d'Achille | Apophysite ; CalcanéusÉtats-Unis
-
Medical Research CouncilComplétéHémorragie post-partum Sever Saignement après l'accouchement
Essais cliniques sur NA: no intervention
-
Samsung Medical CenterPas encore de recrutement
-
Institut CurieRecrutementNeuroblastome | Ganglioneuroblastome | GanglioneuromeFrance
-
STEBA FranceSTEBA LABORATORIES LTD.ComplétéReflux gastro-oesophagien | Oesophagite | L'ulcère duodénal | Ulcère de l'estomacÉtats-Unis
-
University Health Network, TorontoInconnue
-
Boehringer IngelheimComplété
-
Otsuka Pharmaceutical Factory, Inc.CelerionComplété
-
University College, LondonActif, ne recrute pas
-
HaEmek Medical Center, IsraelTechnion, Israel Institute of TechnologyInconnuePlacenta accreta, troisième trimestreIsraël
-
University of ManitobaInconnue
-
University of MinnesotaComplété